Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 35 - Antineoplastic agents
Patents for A61P 35 - Antineoplastic agents (221,099)
09/2014
09/18/2014WO2014139144A1 Therapeutic compounds and compositions
09/18/2014WO2014139131A1 Use of egfr biomarkers for the treatment of gastric cancer with anti-egfr agents
09/18/2014WO2014138912A1 Luminescent compounds and methods of using same
09/18/2014WO2014138819A1 Agents that neutralize il-3 signaling and uses thereof
09/18/2014WO2014138806A1 Oxprenolol compositions for treating cancer
09/18/2014WO2014138805A1 Anti il-3r alpha agents and uses thereof
09/18/2014WO2014138802A1 Canrenoate compositions for treating cancer
09/18/2014WO2014138796A1 Dosage regimen for therapeutic method
09/18/2014WO2014138791A1 Transgenic non-human organisms with non-functional tspo genes
09/18/2014WO2013149159A9 Anti-lgr5 antibodies and immunoconjugates
09/18/2014US20140275618 Therapeutic compounds and methods of use
09/18/2014US20140275479 Specific binding agents of human angiopoeitin-2
09/18/2014US20140275225 Modulators of pharmacological agents
09/18/2014US20140271817 Novel glycoconjugates, glycoamino acids, intermediates thereto, and uses thereof
09/18/2014US20140271695 Immunogenic lhrh compositions and methods relating thereto
09/18/2014US20140271637 Methods of administering anti-tnfalpha antibodies
09/17/2014EP2778175A1 Humanized anti-interleukin 3 receptor alpha chain antibodies for use in treating acute myeloid leukemia (AML)
09/17/2014EP2778156A1 Phenoxypyridinylamide derivatives and their use in the treatment of PDE4 mediated disease states
09/17/2014EP2778155A1 2-aminopyridine derivatives useful as kinase inhibitors
09/17/2014EP2777715A1 Particles comprising luminescent lanthanide complexes
09/17/2014EP2777713A1 Polyethylene glycol-amino acid oligopeptide-irinotecan drug conjugate and drug composition thereof
09/17/2014EP2777707A1 Method of Treating Brain Tumors
09/17/2014EP2777706A1 Methods for increasing the production or activity of catalase
09/17/2014EP2777704A2 Treatment of imatinib resistant leukemia using 4-aminoquinoline-3-carbonitriles
09/17/2014EP2776832A1 Biomarkers for bladder cancer and methods using the same
09/17/2014EP2776468A2 Methods of inhibiting tumor growth by antagonizing il-6 receptor
09/17/2014EP2776451A1 Cyclin a1-targeted t-cell immunotherapy for cancer
09/17/2014EP2776445A1 Therapeutically active thiazolo-pyrimidine derivatives
09/17/2014EP2776444A1 Dihydropteridinones
09/17/2014EP2776437A1 Modulators of opioid receptors and methods of use thereof
09/17/2014EP2776436A1 New compounds
09/17/2014EP2776435A1 Anticancer pyridopyrazines via the inhibition of fgfr kinases
09/17/2014EP2776432A1 Aminopyrimidine kinase inhibitors
09/17/2014EP2776429A1 Compounds useful as inhibitors of atr kinase
09/17/2014EP2776427A1 Modulators of atp-binding cassette transporters
09/17/2014EP2776422A1 Compounds useful as inhibitors of atr kinase
09/17/2014EP2776421A1 Compounds useful as inhibitors of atr kinase
09/17/2014EP2776417A1 5-(pyridin-2-yl-amino)-pyrazine-2-carbonitrile compounds and their therapeutic use
09/17/2014EP2776413A1 TREATMENT OF OVARIAN CANCER WITH 2-AMINO-4H-NAPHTHO[1,2-b]PYRAN-3-CARBONITRILES
09/17/2014EP2776409A1 Macrocyclic compounds for inhibition of inhibitors of apoptosis
09/17/2014EP2776406A2 Erlotinib salts
09/17/2014EP2776404A1 Heterocyclic analogs of propargyl-linked inhibitors of dihydrofolate reductase
09/17/2014EP2776402A1 Meldrum 's acid, barbituric acid and pyrazolone derivatives substituted with hydroxylamine as hno donors
09/17/2014EP2776397A1 Quinolines as fgfr kinase modulators
09/17/2014EP2776394A1 (hetero)aryl cyclopropylamine compounds as lsd1 inhibitors
09/17/2014EP2776393A1 Nampt inhibitors
09/17/2014EP2776067A1 Composition for photodynamic diagnosis and treatment of tumors
09/17/2014EP2776064A1 Provasopressin antagonists and uses thereof
09/17/2014EP2776054A2 Antagonists for abnormal vasopressin v2 receptor and uses thereof
09/17/2014EP2776051A1 Therapeutic combinations and methods of treating melanoma
09/17/2014EP2776043A1 Biomarkers of response to proteasome inhibitors
09/17/2014EP2776037A1 Method of treating a proliferative disease
09/17/2014EP2776033A1 Dual inhibitor of met and vegf for treating cancer
09/17/2014EP2776032A2 Treatment of hematologic malignancies with an anti-cxcr4 antibody
09/17/2014EP2776031A1 N-methyl-2-[3-((e)-2-pyridin-2-yl-vinyl)-1h-indazol-6-ylsulfanyl]-benzamide for the treatment of chronic myelogenous leukemia
09/17/2014EP2776029A1 Treatment of ovarian cancer with benzylidenebenzohydrazides
09/17/2014EP2776025A1 Combination therapy of hsp90 inhibitors with platinum-containing agents
09/17/2014EP2776021A1 Administration of a bis(thiohydrazide amide) compound for treating cancers
09/17/2014EP2776020A1 Methods for the treatment of skin neoplasms
09/17/2014EP2776017A1 Gold compounds having alkynyl ligands and therapeutic use thereof
09/17/2014EP2775921A1 Method of quantifying cancer treatment
09/16/2014US8835693 Migrastatin analogs and uses thereof
09/16/2014US8835629 Anti-cancer agents
09/16/2014US8835611 Calicheamicin derivative-carrier conjugates
09/16/2014US8835450 Combination of inhibitor of B-Raf and an inhibitor of Akt in the treatment of cancer
09/16/2014US8835435 2-(3-aminoaryl) amino-4-aryl-thiazoles and their use as c-kit inhibitors
09/16/2014US8835434 Hydroxylated pyrimidyl cyclopentanes as akt protein kinase inhibitors
09/16/2014US8835401 Treatment of cancer by inhibition of IGFBPs and clusterin
09/16/2014US8835394 Treatment for basal cell carcinoma
09/16/2014US8835393 Inhibitors of IAP
09/16/2014US8834900 Combination motif immune stimulatory oligonucleotides with improved activity
09/16/2014US8834897 Methods for using tetanus toxin for beneficial purposes in animals (mammals)
09/16/2014US8834876 Therapeutic agent for hematopoietic tumors
09/16/2014US8834875 Notch1 binding agents and methods of use thereof
09/16/2014US8834837 Method and device for radiotherapy
09/16/2014CA2781066C Compound, certain novel forms thereof, pharmaceutical compositions thereof and methods for preparation and use
09/16/2014CA2727830C Methods and compositions using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment and management of multiple myeloma
09/16/2014CA2607228C Compositions and methods using microspheres and non-ionic contrast agents
09/16/2014CA2604895C (1h-indol-7-yl)-( (pyrimidin-2-ylamino) methanone derivatives and related compounds as igf-r1 inhibitors for the treatment of cancer
09/16/2014CA2583367C Cytotoxic formulation for combination therapy
09/16/2014CA2570887C Tumor treatment
09/16/2014CA2526240C 7a5/prognostin and use thereof for the diagnostic and therapy of tumors
09/16/2014CA2484420C Antibodies specific for human cd22 and their therapeutic and diagnostic uses
09/12/2014WO2014138727A1 Suppression of malignant mesothelioma by overexpression or stimulation of endothelial protein c receptors (epcr)
09/12/2014WO2014138556A1 Kits and methods for the treatment of cancer using gliadin peptides
09/12/2014WO2014138449A1 Anti-c-met tandem fc bispecific antibodies
09/12/2014WO2014138391A1 Targeting glutamine metabolism in brain tumors
09/12/2014WO2014138278A1 Lipid bilayer coated mesoporous silica nanoparticles with a high loading capacity for one or more anticancer agents
09/12/2014WO2014138075A1 Phosphonic acid compounds as sphingosine-1-phosphate receptor modulators
09/12/2014WO2014137141A1 Interleukin-8 aptamer and use thereof
09/12/2014WO2014136910A1 ANTIBODY TO PEPTIDE ENCODED BY Exon-21 OF PERIOSTIN, AND PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF INFLAMMATORY DISEASE CONTAINING SAID ANTIBODY
09/12/2014WO2014136845A1 Method for producing mature dendritic cell population
09/12/2014WO2014136814A1 Novel peptide having 5 linked ctl epitopes
09/12/2014WO2014136786A1 Novel compound
09/12/2014WO2014136453A1 C12orf48 PEPTIDES AND VACCINES CONTAINING THE SAME
09/12/2014WO2014136161A1 Osteopontin production inhibitor comprising dictyopyrone derivative or dihydrodictyopyrone derivative as active ingredient
09/12/2014WO2014135934A1 Camelid compound(s), composition(s) and method(s)
09/12/2014WO2014135851A1 Combination treatment
09/12/2014WO2014135834A1 Oxalic acid addition salts and/or solvates of a selective estrogen receptor modulator
09/12/2014WO2014135776A1 Novel abexinostate salt, associated crystalline form, preparation method thereof and the pharmaceutical compositions containing same
1 ... 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 ... 2211